Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPepVac: Personalized Neo-antigen Vaccine + Anti-PD-1/L1 in Advanced Solid Tumors
NCT03715985Phase 2Unknown
- Sponsor
- Herlev Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Targeted Liposomes, Split/Subunit Vaccines, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of EVX-01 in melanoma, bladder urothelial carcinoma, sponsored by Herlev Hospital. Status: unknown.
02
Drugs
EVX-01
03
Conditions
melanomabladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03715985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715985.